Cargando…

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Detalles Bibliográficos
Autores principales:	Ornstein, Moshe C., Wood, Laura S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427515/ https://www.ncbi.nlm.nih.gov/pubmed/37233877 http://dx.doi.org/10.1007/s12325-023-02513-1

Ejemplares similares

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma
por: Ivanyi, Philipp, et al.
Publicado: (2023)

First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
por: Ivanyi, Philipp, et al.
Publicado: (2023)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Living with Type 2 Diabetes: Podcast of a Patient–Physician Discussion
por: Kushner, Pamela, et al.
Publicado: (2023)

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
por: Huang, Jiwei, et al.
Publicado: (2021)

A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift
por: Epstein, Murray
Publicado: (2022)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Genetic Testing in Metastatic Breast Cancer in the USA: A Podcast
por: Basho, Reva, et al.
Publicado: (2023)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 2: Negative Symptoms in Schizophrenia [Podcast]
por: Racher, Matthew, et al.
Publicado: (2023)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
por: Lu, Peiyao, et al.
Publicado: (2020)

Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies
por: Lafayette, Richard A., et al.
Publicado: (2023)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
por: Patel, Sandip, et al.
Publicado: (2023)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
por: Koie, Takuya, et al.
Publicado: (2015)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Tzeng, Alice, et al.
Publicado: (2021)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
por: Zakharia, Yousef, et al.
Publicado: (2022)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast]
por: Larrauri, Carlos A, et al.
Publicado: (2023)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
por: Uekawa, Ayano, et al.
Publicado: (2022)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022)

Cultivating a Community of Practice through Podcasting
por: Zumach, Gregory M., et al.
Publicado: (2020)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
por: Choueiri, T. K., et al.
Publicado: (2020)

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
por: Sheng, Iris Y, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m9kchd8rf3g79e3spluknkdbh8